Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $3.0 million.

  • Nurix Therapeutics' Change in Account Payables fell 6011.87% to $3.0 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$630000.0, marking a year-over-year decrease of 11209.45%. This contributed to the annual value of -$630000.0 for FY2025, which is 11209.45% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Change in Account Payables stood at $3.0 million, which was down 6011.87% from $2.2 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Change in Account Payables ranged from a high of $7.6 million in Q4 2024 and a low of -$3.2 million during Q1 2025
  • Its 5-year average for Change in Account Payables is $393350.0, with a median of $148500.0 in 2022.
  • Per our database at Business Quant, Nurix Therapeutics' Change in Account Payables surged by 61724.14% in 2023 and then plummeted by 33250.0% in 2024.
  • Nurix Therapeutics' Change in Account Payables (Quarter) stood at $862000.0 in 2021, then plummeted by 204.29% to -$899000.0 in 2022, then soared by 617.24% to $4.6 million in 2023, then skyrocketed by 63.12% to $7.6 million in 2024, then plummeted by 60.12% to $3.0 million in 2025.
  • Its Change in Account Payables stands at $3.0 million for Q4 2025, versus $2.2 million for Q3 2025 and -$2.7 million for Q2 2025.